Hypercalcemia Cell Models for Research

Hypercalcemia is a common electrolyte disorder, affecting approximately 1% of the general population and up to 30% of cancer patients (WHO, 2023). Primary hyperparathyroidism (PHPT) is the leading cause in outpatients, while malignancy-associated hypercalcemia (MAH) is the most common cause in hospitalized patients. The incidence of PHPT is estimated at 25-30 per 100,000 person-years, with a female-to-male ratio of 3:1 (NCI, 2023). MAH occurs in about 20-30% of patients with advanced cancers, particularly lung, breast, and multiple myeloma. The 5-year survival for cancer patients with hypercalcemia is poor, with a median survival of only 3-4 months (NCI, 2023). Hypercalcemia can lead to nephrolithiasis, renal failure, and neuropsychiatric symptoms, and severe hypercalcemia (calcium >14 mg/dL) is a medical emergency.

Hypercalcemia is an ideal model for studying calcium homeostasis, bone metabolism, and endocrine signaling. It involves multiple organ systems and has well-defined molecular pathways. Public datasets such as TCGA and COSMIC provide extensive genomic data on tumors associated with hypercalcemia. Open questions include the mechanisms of parathyroid hormone (PTH) secretion, the role of parathyroid hormone-related protein (PTHrP) in malignancy, and the regulation of vitamin D metabolism. Gene-edited cell models enable precise manipulation of key genes (e.g., PTH, PTHrP, CYP27B1) to dissect these pathways.

Hypercalcemia arises from dysregulated calcium-sensing mechanisms. Key pathways include:

• • Parathyroid hormone (PTH) signaling: PTH binds to PTH1R, activating adenylate cyclase and phospholipase C, leading to increased bone resorption and renal calcium reabsorption.
• • Parathyroid hormone-related protein (PTHrP) signaling: PTHrP mimics PTH actions, often overexpressed in tumors, causing humoral hypercalcemia of malignancy.
• • Vitamin D metabolism: Overproduction of 1,25-dihydroxyvitamin D (calcitriol) by macrophages or tumors increases intestinal calcium absorption.
• • Calcium-sensing receptor (CaSR) mutations: Loss-of-function mutations in CaSR cause familial hypocalciuric hypercalcemia (FHH) and neonatal severe hyperparathyroidism.

Data from TCGA and COSMIC (2023).

Hypercalcemia involves several signaling networks:

• • PTH/PTHrP signaling: PTH1R activation leads to cAMP/PKA and PLC/PKC pathways, regulating RANKL and osteoprotegerin (OPG) expression in bone.
• • Calcium-sensing receptor (CaSR) signaling: CaSR activates Gq/11 and Gi/o, modulating PTH secretion and renal calcium handling.
• • Vitamin D receptor (VDR) signaling: Calcitriol binds VDR, regulating intestinal calcium absorption and bone remodeling.
• • RANK/RANKL/OPG axis: Key in osteoclast activation and bone resorption.

Organoids derived from parathyroid tumors or bone metastases can recapitulate 3D architecture and cell-cell interactions, providing more physiologically relevant models for studying hypercalcemia.

• • Patient-derived xenografts (PDX): Implantation of human tumors into immunodeficient mice to study tumor-induced hypercalcemia.
• • Genetically engineered mouse models (GEMM): Knockout of Men1 or CaSR to model PHPT or FHH.
• • Induced models: Administration of PTH or PTHrP to mice to induce hypercalcemia.
• • Vitamin D-induced models: High-dose calcitriol to mimic hypercalcemia.

CRISPR-Cas9 gene editing enables the creation of isogenic cell lines with precise modifications. For hypercalcemia research, commercially available gene-edited models include:

• • PTH knockout cell lines: In parathyroid-derived cells, to study PTH secretion and regulation.
• • PTHrP knock-in cell lines: Overexpressing PTHrP in cancer cells to model humoral hypercalcemia.
• • CaSR knockout cell lines: To study calcium sensing and signaling.
• • CYP27B1 knockout cell lines: To investigate vitamin D metabolism.

These sequence-verified models are available from commercial sources and accelerate research by providing consistent, reproducible systems.

Gene-edited cell lines are used to validate the function of genes involved in calcium homeostasis. For example:

• • Knockout of PTH in parathyroid cells to confirm its role in calcium regulation.
• • Knock-in of PTHrP in non-expressing cells to study its oncogenic effects.
• • CRISPR-mediated mutation of CaSR to assess its impact on signaling pathways.

Isogenic pairs (wild-type vs. knockout) are used to screen for drugs that target specific pathways. For instance:

• • Screening for calcimimetics that activate CaSR in CaSR knockout vs. wild-type cells.
• • Testing bisphosphonates in PTHrP-overexpressing cells to evaluate their efficacy in reducing bone resorption.
• • Resistance modeling: Cells with acquired resistance to calcimimetics can be generated by chronic exposure, and gene editing can identify resistance mechanisms.

CRISPR screens can identify novel biomarkers and therapeutic targets. For example:

• • Synthetic lethality screens in PTHrP-overexpressing cells to find genes essential for survival.
• • Genome-wide knockout screens to identify regulators of PTH secretion.
• • Transcriptomic analysis of edited cells to discover secreted factors that contribute to hypercalcemia.